RxDoctor Payments Data

Antoinette Pragalos, MD

Internal Medicine · Cincinnati, OHNPI 1851393730

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,018 of the $1,333 with a category attached, or 76.3%. Modernatx, Inc. accounts for 98.8% of it on its own, with 1 other manufacturer making up the rest.

$1,333in general payments, 2019–2025

Across 11 payments — averaging $121.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$1K
  • Novo Nordisk$16
$27,789,140in research payments, 2019–2025

Across 3,025 payments — averaging $9186.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$12.2M
  • Modernatx, Inc.$8.6M
  • Pfizer$2M
  • Biontech SE$1.6M
  • Bavarian Nordic A/s$941K
  • Merck$892K
  • plus $1.5M from 5 others

What the payments were for

  • Travel & lodging$1,01876%
  • Food & beverage$31624%

General payments by program year

20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.10$1,318
Novo Nordisk1$16

How this compares

$1,333 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$55,582
Medicare patients
285
Services billed
1,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$121,953
JanuviaSitagliptin Phosphate44$46,105
EliquisApixaban58$41,803
MounjaroTirzepatide34$35,453
JardianceEmpagliflozin20$29,348
ProliaDenosumab12$20,824
TrulicityDulaglutide12$16,911
MyrbetriqMirabegron16$11,607
PremarinEstrogens, Conjugated14$7,270
Advair HfaFluticasone Propion/Salmeterol12$4,890
DuleraMometasone/Formoterol14$4,750
Levothyroxine Sodium477$4,073
Atorvastatin Calcium507$3,424
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,089
Losartan Potassium294$2,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$121,953102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →